2026 Eastern States Conference

Authors:
Ali Al Ali, BA, PharmD; Debra Wilner, BA, PharmD, BCIP; Amanda S. Rampersaud, PharmD, BCPS

Learning Objective:
Describe the appropriateness of cabotegravir-rilpivirine use and its impact on treatment outcomes in patients with human immunodeficiency virus

Background/Objective:
Evaluate the appropriateness of cabotegravir and rilpivirine use based on approved indications and assess treatment outcomes in patients with human immunodeficiency virus.

Methods:
This retrospective, single-center study evaluated adults aged 18 years and older who received at least one dose of cabotegravir and rilpivirine between September 1, 2023 and September 1, 2025 at an urban healthcare system. Appropriateness was defined based on approved indications including virologic suppression, no history of treatment failure, and no known or suspected resistance. Primary outcomes included appropriateness of use and rates of treatment failure.

Results:
Pending

Conclusions:
Pending